Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five ...

The congenital hyperinsulinism market has demonstrated remarkable growth, attributed to increasing awareness, early diagnosis, and the rise of personalized treatments. Valued at USD 194.5 billion in ...

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has demonstrated ...

A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results ...

(NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital hyperinsulinism ...

From the Peter Bent Brigham Hospital, Boston, Mass. Derick — Physician, Peter Bent Brigham Hospital. Newton — Senior Associate in Surgery, Peter Bent Brigham Hospital. Schulz — Instructor in ...

Introduction: Congenital hyperinsulinism (HI) is characterized by inappropriate insulin secretion from the pancreatic beta-cells which causes severe hypoglycemia. Copy number variants (CNVs) ...

Background: The diagnosis of congenital hyperinsulinism (CHI) may be hampered by a plasma (p-) insulin detection limit of 12–18 pmol/L (2–3 mU/L). Objective: To evaluate the diagnostic performance of ...